Advertisement

Related Videos

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Gary L. Rosner, ScD, on Bayesian Non-Inferiority

David A. Hyman, MD, JD, on Inclusive Shared Savings

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Focus on Optimized Dosing of Ibrutinib Panel Discussion

Advertisement

Advertisement




Jul
18
Today In Oncology
COVID-19 Boosters Offer Protection for Patients With Cancer
Can Use of Aprepitant During Chemotherapy Improve Triple-Negative Breast Cancer Outcomes
Urothelial Cancer Survival in the Eras Before and After Immune Checkpoint Inhibitors and Antibody-Drug Conjugates
Early ctDNA Change and Outcomes With ICI Treatment in Metastatic Colorectal Cancer
Classifying Pancreatic Cysts Using AI Models
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo